April 3, 2017 09:47 AM EDTUpdated 10:14 AM

Roche scores a success for Alecensa PhIII; FDA schedules AdComm for Heplisav-B; New CMO at Sarepta

Shehla Shakoor

Managing Director

→ Roche reported this morning that its latest Phase III study for Alecensa (alectinib) came through, hitting the endpoint on progression-free survival for non …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche scores a success for Alecensa PhIII; FDA schedules AdComm for Heplisav-B; New CMO at Sarepta

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Roche scores a suc­cess for Ale­cen­sa PhI­II; FDA sched­ules Ad­Comm for Hep­lisav-B; New CMO at Sarep­ta

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Roche scores a success for Alecensa PhIII; FDA schedules AdComm for Heplisav-B; New CMO at Sarepta

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?